Expression of PD-1 and PD-L1 in endometrial cancer: molecular and clinical significance

MN Mamat@ Yusof, KT Chew, NC Kampan… - International Journal of …, 2023 - mdpi.com
The landscape of diagnosing and treating endometrial cancer is undergoing a profound
transformation due to the integration of molecular analysis and innovative therapeutic …

Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis

G Yan, Y Du, H Zhang, J Yan, Y Liu, Z Ban… - Frontiers in …, 2024 - frontiersin.org
Background Various trials have demonstrated the clinical benefits of lenvatinib plus
pembrolizumab in patients with advanced or recurrent endometrial cancer, regardless of …

DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer

F Guo, R Lu, W Kong, M Anwar, Y Feng - Cancer Cell International, 2024 - Springer
Background Cervical cancer (CC) is a potential clinical application of PD-1/PD-L1 inhibitor.
We aimed to study the mechanism of DNA mismatch repair (MMR) system regulating the …

Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review

MD Velimirovici, CVI Feier, RC Vonica, AM Faur… - Biomedicines, 2024 - mdpi.com
Background and objectives: The efficacy and safety of PD-L1 inhibitors in the treatment of
cervical cancer is an ongoing research question. This review aims to establish a clear profile …

Prognostic significance of the immune microenvironment in endometrial cancer

M Lee, W Jung, J Kang, KH Lee, SJ Lee, SH Hong… - Laboratory …, 2024 - Elsevier
This study used artificial intelligence (AI)-based analysis to investigate the immune
microenvironment in endometrial cancer (EC). We aimed to evaluate the potential of AI …

Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis

P Ji, J He - Biomarkers in medicine, 2024 - Taylor & Francis
Background: The present work focused on evaluating the systemic immune-inflammation
index (SII) for its role in predicting endometrial cancer (EC) patient prognosis by meta …

[HTML][HTML] The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations

A Santoro, G Angelico, F Inzani, D Arciuolo… - Gynecologic …, 2024 - Elsevier
Over recent years, there has been significant progress in the development of
immunotherapeutic molecules designed to block the PD-1/PD-L1 axis. These molecules …

[HTML][HTML] Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer

ST Waluyo, BA Tjokroprawiro, AS Rahaju - European Journal of Obstetrics …, 2024 - Elsevier
Objective To determine the effect of estrogen receptor (ER) on programmed death-ligand 1
(PD-L1) expression in type I endometrial cancer (EC). Material and Methods This …

The distribution characteristics of PD-1 pathway related immune cells in esophageal cancer tissue and their relationship with prognosis

D Kong, C Gao, Y Yang, L Yang, J Ma, S Tang, Y Mao… - 2024 - researchsquare.com
Purpose Exploring the distribution characteristics of immune cells related to the programmed
cell death receptor-1 (PD-1) pathway in esophageal cancer (EC) tissue and its relationship …

Causal Relationship Between Immune Cells and Endometrial Cancer: A Two-Sample Mendelian Randomization Study

XF Leng, HJ Yao, H Yin, KK Zeng, A Kanneganti… - 2024 - researchsquare.com
Background In the context of endometrial cancer (EC), immune cells are pivotal in
influencing tumor progression and outcome, exerting effects predominantly via mechanisms …